An antiseptic composition comprising a multivalent cationic antiseptic present in an amount of 0.05 to 0.5 percent based upon the ready to use composition; an anionic compound which is water soluble in an amount of at least 0.1 grams in 100 grams water at 23 deg C., wherein the anionic compound is present at a concentration which would result in precipitation of the multivalent cationic antiseptic in the composition without a solubilizing surfactant present; wherein the composition, with the antiseptic, surfactant and anionic compound combined with each other, is free of precipitate.

The present invention relates to noninvasive microbiome analyses of Barrett's esophagus (BE) patients in which changes in the relative abundance of certain bacteria indicate a disease likelihood or pathogenic state. Additional aspects of the present invention relate to manipulating the microbiome to treat or prevent BE and related conditions. Embodiments also include monitoring for development of disease or monitoring treatment for prevention or elimination of disease states.

Antimicrobial polymer coating formulations are prepared that protect biological surfaces by treating, reducing, ameliorating, preventing or inhibiting pathogenic microorganism ingress to a human or animal host, reducing the potential for infection, particularly by necrotizing fasciitis originating microorganisms, through use of a polymer coating barrier containing antimicrobial agents that facilitates sustained release of biocidal agents active against such opportunistic microorganisms. Such formulations are effective for inhibiting microbial ingress pertaining to soft tissue and skin tears, abrasions, punctures and surgical wounds, and can be used as in water environments and as a skin protectant sunscreen and insect repellent.

A combination of at least one selected dicarboxylic acid having 2 to 10 carbon atoms, in combination with at least one amino acid, selected from arginine, lysine, histidine or at least one of the salts of these amino acids, form a bleaching paste in order to reduce the damage to keratinic fibres caused by an oxidative bleaching treatment.

An antiseptic solution comprising a pH-dependent antimicrobial agent, the pH-dependent antimicrobial agent having an operative pH range, wherein the solution has a pH on storage that is lower than the operative pH range. Applicators for applying the antiseptic solution and methods of using the antiseptic solution and applicators are also provided.

The invention relates to multi-action dermatological compositions that provides lightening, protecting and anti-aging effects to the skin of a user. The composition comprises niacinamide, arbutin, tranexamic acid, ubiquinone, a DHEA-like component, curcuma oily extract and marine exopolysaccharides. The invention also relates to methods of dermatological treatment and a method of treating hyperpigmentation by applying the composition to the skin of a user.

The present invention provides a skin cosmetic containing the following components (A), (B), (C), (D), (E), and (F): (A) 0.5 to 7 mass % of a linear saturated fatty acid having 12 to 22 of carbon atom, (B) 0.01 to 5 mass % of an organic base, (C) 0.01 to 1 mass % of an inorganic base, (D) 0.6 to 7 mass % of a linear saturated alcohol having 12 to 22 of carbon atom, (E) 0.1 to 20 mass % of an oil agent, and (F) water, wherein
the total amount of the components (A) and (D) is (A)+(D)=from 1 to 14 mass %, the mass ratio of the component (A) to the total amount of the components (A) and (D) [(A)+(D)] is (A)/[(A)+(D)]=from 0.1 to 0.9, the molar ratio of the component (B) to the total amount of the components (B) and (C) [(B)+(C)] is (B)/[(B)+(C)]=from 5 to 50 mol %, and the molar ratio of the total amount of the components (B) and (C) [(B)+(C)] to the component (A) is [(B)+(C)]/(A)=more than 80 mol % and 120 mol % or less.

The present invention provides a skin cosmetic containing the following components (A), (B), (C), (D), (E), and (F): (A) 0.5 to 7 mass % of a linear saturated fatty acid having 12 to 22 of carbon atom, (B) 0.01 to 5 mass % of an organic base, (C) 0.01 to 1 mass % of an inorganic base, (D) 0.6 to 7 mass % of a linear saturated alcohol having 12 to 22 of carbon atom, (E) 0.1 to 20 mass % of an oil agent, and (F) water, wherein
the total amount of the components (A) and (D) is (A)+(D)=from 1 to 14 mass %, the mass ratio of the component (A) to the total amount of the components (A) and (D) [(A)+(D)] is (A)/[(A)+(D)]=from 0.1 to 0.9, the molar ratio of the component (B) to the total amount of the components (B) and (C) [(B)+(C)] is (B)/[(B)+(C)]=from 5 to 50 mol %, and the molar ratio of the total amount of the components (B) and (C) [(B)+(C)] to the component (A) is [(B)+(C)]/(A)=more than 80 mol % and 120 mol % or less.

The invention concerns a pharmaceutical composition comprising a platelet lysate and its use to treat a wound, an anal fissure, vaginal atrophy or a wrinkle.

An oral care composition comprising: (a) arginine, in free or salt form; and (b) zinc oxide and zinc citrate. The oral care composition can reduce or inhibit biofilm formation in an oral cavity.